Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients.
We assess the efficacy of pegylated interferon (peg-IFN) with ribavirin (RBV) and the predictors of sustained virological response (SVR) among HIV/hepatitis C virus genotype 4 (HCV-4)-coinfected patients. Thirty-nine (31.5%) of 124 individuals with HCV-4 achieved SVR compared with 103 (22.7%) of 453 individuals with HCV genotype 1 (P=0.046). Only interleukin-28B (IL28B) genotype CC was independently associated with SVR in HIV/HCV-4-coinfected patients. The efficacy of peg-IFN with RBV in coinfected individuals with genotype 4 is significantly higher than in those with genotype 1. IL28B CC genotype is the main predictor of response in this population.
Unidad de Enfermedades Infecciosas y Microbiología Clínica, Hospital Universitario de Valme, Seville, Spain.
José A
JA
Mira
Antonio
A
Rivero
Ignacio
I
de Los Santos-Gil
Luis F
LF
López-Cortés
José A
JA
Girón-González
Manuel
M
Márquez
Dolores
D
Merino
María
M
del Mar Viloria
Francisco
F
Téllez
María J
MJ
Ríos-Villegas
Mohamed
M
Omar
Antonio
A
Rivero-Juárez
Juan
J
Macías
Juan A
JA
Pineda
D000998:Antiviral Agents / Q000494:pharmacology*; D060085:Coinfection; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy*; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology*; D008297:Male; D011092:Polyethylene Glycols / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology; D012254:Ribavirin / Q000494:pharmacology*; D016896:Treatment Outcome
D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a